The American Society for Colposcopy and Cervical Pathology (ASCCP). Module 2: What is the Role of HPV Testing.

The American Society for Colposcopy and Cervical Pathology (ASCCP)

Webinar.

Activity Summary:

Studies have shown that certain Human papillomavirus (HPV) types are a requisite for the development of cervical cancer and other cancers of the lower genital tract. The introduction of molecular testing for HPV has facilitated the earlier detection of cervical cancer precursors and identify those women at greatest risk of future disease. Today there are multiple methods of screening for cervical precancer and clear information is needed to sort out which tests offer the greatest opportunity to assure most women that they do not have disease risk, and identify those women early at risk of current and future cervical neoplasia.

This CME activity, Module 2, consists of a panel discussion on HPV screening of women 25 – 29 years of age. Panelists will discuss the current screening recommendations for women 25 – 29 years of age, performance of different screening strategies, benefits of using cervical cytology and HPV testing, and effects of HPV vaccination on screening.

Audience:

This activity is intended for clinicians from a variety of specialties including obstetrics and gynecology, family medicine and, internal medicine, for residents in obstetrics/gynecology and family medicine, for advanced practice clinicians working in family planning and other community clinics, private offices and hospital settings, for pathologists who supervise residents and fellows, and for physicians with administrative responsibility for gynecology patients.

Learning Objectives:

Upon completion of the course, participants will:

• Understand the epidemiology of HPV and cervical neoplasia
• Understand consensus screening and management guidelines and the new guidance for primary HPV screening and how to apply them in a clinical setting
• Understand methods and rationale for screening women under age 30
• Understand important differences between the use of specific laboratory developed testing techniques and those that have undergone intense testing and validation and achieved FDA approval and licensing.
• Understanding the effect of vaccines on cervical cancer screening in the future.

CME Information:

• ACCME Accreditation

The American Society for Colposcopy and Cervical Pathology (ASCCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

• Continuing Medical Education Credits

The American Society for Colposcopy and Cervical Pathology designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty/Disclosures:

• Walter K. Kinney, MD
  Clinical Professor of Obstetrics and Gynecology
  University of California, Davis
  Division Director
  Gynecologic Oncology
  The Permanente Medical Group
  Sacramento, California
• Herschel W. Lawson, MD
  Chief Medical Officer, ASCCP
  Adjunct Associate Professor
  Emory University School of Medicine
  Atlanta, Georgia
• Thomas C. Wright, Jr, MD
  Past President, ASCCP
  Professor Emeritus of Pathology and Cell Biology
  Columbia University Medical Center
  New York, New York

Moderator:

• Warner K, Huh, MD
  Professor
  Division of Gynecologic Oncology
  Department of Obstetrics and Gynecology
  University of Alabama, Birmingham
  Birmingham, Alabama